Evidence map›Paper›PMID 40919679›Full record

ReviewClinical and experimental immunology2025

Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps.

Anju T Peters, Joseph K Han, Enrico Heffler, Freyja McClenahan, Scott Caveney, Tham T Le, Ayman Megally, Joseph D Spahn, Andrew Foster, Joseph D Sherrill

Abstract readReview
In one paragraph

Review in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anju T PetersDivision of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0003-0745-2379
Joseph K HanDepartment of Otolaryngology - Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
Enrico HefflerPersonalized Medicine Asthma and Allergy Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Freyja McClenahanPharmaGenesis London, London, UK.
Scott CaveneyGlobal Development, Inflammation, R&D, Amgen, Thousand Oaks, CA, USA.
Tham T LeBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Ayman MegallyLate-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Joseph D SpahnRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Andrew FosterRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Joseph D SherrillTranslational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Funding

Amgen IncAstraZeneca
6 · The paper itself

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa, predominantly characterized by epithelial dysfunction and chronic heterogeneous mucosal inflammation. CRSwNP and asthma are common comorbidities with overlapping pathophysiology, epithelial impairment, and activation of downstream type 2 inflammation. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that sits at the top of the immunological cascade and initiates and amplifies type 2-dependent and -independent inflammatory responses. Although the role of TSLP in asthma has been well described, the role of TSLP in CRSwNP has yet to be comprehensively outlined. This review examines the evidence for TSLP as a key factor in CRSwNP pathogenesis. We explore what is known about TSLP expression patterns within the sinonasal mucosa, finding that TSLP expression is increased in patients with CRSwNP compared with healthy patients, and in eosinophilic- versus non-eosinophilic CRSwNP. We discuss the impact of environmental triggers and genetic factors on TSLP expression and activity, as well as other upstream regulators of TSLP signaling. We then consider the known mechanisms and effects of TSLP signaling on the recruitment and activation of various immune and structural cell types in CRSwNP. Finally, we consider the available evidence on the therapeutic potential of targeting TSLP signaling for the treatment of CRSwNP and discuss ongoing trials of promising therapeutic candidates.

Indexed as

CytokinesNasal MucosaNasal PolypsRhinitisSinusitisAnimalsChronic DiseaseHumansRhinosinusitisSignal TransductionThymic Stromal LymphopoietinCytokinesThymic Stromal LymphopoietinTSLP protein, humancytokineseosinophilsinflammationmucosa

Identifiers

PMID40919679
PMCPMC12449146

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.